Tivantinib (ARQ197; by Arqule, Inc.) is an experimental small molecule anti-cancer drug.

It is a bisindolylmaleimide that binds to the dephosphorylated MET kinase in vitro.

Tivantinib is being tested clinically as a highly selective MET inhibitor.

[citation needed] Tivantinib displays cytotoxic activity via molecular mechanisms that are independent from its ability to bind MET, notably tubulin binding, which likely underlies tivantinib cytotoxicity.

[3] In 2017, it was announced that a phase III clinical trial for advanced hepatocellular carcinoma had failed to meet the primary endpoint.